Bimzelx · DIN 02525267 · 160 mg/mL · injection, 1 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 641 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 641 required
Write on scriptReason for Use code 641 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 641
Reason for Use code 641
For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).
Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.
Note 1: Definition of severe plaque psoriasis:
- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face,
hands, feet or genital regions, AND
- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND
- Dermatology Life Quality Index (DLQI) score of at least 10.
Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:
- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND
- 12 week trial of phototherapy (unless not accessible), AND
- 6 month trial of at least 2 systemic, oral agents used alone or in combination
- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine
Maintenance/Renewal:
After 3 months of therapy, patients who respond to therapy should have:
- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score
Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Bimzelx · DIN 02525267
Manufacturer: UCB Canada Inc.; listing date 2023-03-31
Health Canada: Marketed since 2022-03-30 · brand BIMZELX · ATC L04AC21 BIMEKIZUMAB · form Solution · route Subcutaneous · ingredients BIMEKIZUMAB 160 MG/ML · company Ucb canada inc · schedule Prescription, Schedule d
Bimzelx: Formulary list price $1625.00 per unit (the source does not state the unit; exact figure $1625.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02525267)
Source record
DIN 02525267: Bimzelx
Raw flags: sec12=Y, sec3=Y
Item: 849200011; group id 870; item number 2105; lccId 00366; manufacturer id UCB
Source form: Inj Sol-1mL Pref Syr (Preservative-Free); strength: 160mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1625.0000; ministry $1625.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02525267
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101427
Shortage status: not checked (no credentials)